• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1型肺动脉高压患者室上性心动过速消融术后的结局

Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension.

作者信息

Satish Tejus, Chin Kelly, Patel Nimesh

机构信息

University of Texas Southwestern Medical Center, Dallas, TX 75390-9030, USA.

出版信息

Cardiol Res. 2023 Oct;14(5):403-408. doi: 10.14740/cr1556. Epub 2023 Oct 21.

DOI:10.14740/cr1556
PMID:37936620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10627367/
Abstract

BACKGROUND

Pulmonary hypertension (PH) is associated with right ventricular pressure overload and atrial remodeling, which may result in supraventricular tachycardias (SVTs). The outcomes of catheter SVT ablation in patients with World Health Organization (WHO) group 1 PH are incompletely characterized.

METHODS

We conducted a retrospective cohort study of all patients with WHO group 1 PH undergoing catheter SVT ablation during a 10-year period at a major academic tertiary care hospital. Baseline patient characteristics and procedural outcomes at 3 months and 1 year were extracted from the electronic medical record.

RESULTS

Ablation of 60 SVTs was attempted in 38 patients with group 1 PH. The initial procedural success rates were 80% for atrial fibrillation (AF, n = 5), 89.7% for typical atrial flutter (AFL, n = 29), 57.1% for atypical AFL (n = 7), 60% for atrial tachycardia (AT, n = 15), and 75% for atrioventricular nodal reentrant tachycardia (AVNRT, n = 4). The 1-year post-procedural recurrence rates were 100% for AF (n = 4), 25% for typical AFL (n = 20), 50% for atypical AFL (n = 2), and 28.6% for AT (n = 7). No patients had recurrent AVNRT (n = 2). There were seven (18.4%) peri-procedural decompensations requiring pressor initiation and transfer to intensive care and one (2.6%) peri-procedural death.

CONCLUSIONS

The study demonstrates that SVT ablation in group 1 PH can be performed relatively safely and effectively, albeit with lower initial success rates and higher risk of clinical decompensation than in the general population. Recurrence rates at 1 year were higher in AF and atypical AFL ablations and similar for typical AFL and AT ablations when compared to the general population.

摘要

背景

肺动脉高压(PH)与右心室压力超负荷及心房重塑相关,这可能导致室上性心动过速(SVT)。世界卫生组织(WHO)1组PH患者行导管消融治疗室上性心动过速的结果尚未完全明确。

方法

我们对一家大型学术三级医疗中心10年间所有接受导管消融治疗室上性心动过速的WHO 1组PH患者进行了一项回顾性队列研究。从电子病历中提取患者的基线特征以及3个月和1年时的手术结果。

结果

38例1组PH患者尝试消融60次室上性心动过速。初始手术成功率分别为:房颤(AF,n = 5)80%,典型房扑(AFL,n = 29)89.7%,非典型AFL(n = 7)57.1%,房性心动过速(AT,n = 15)60%,房室结折返性心动过速(AVNRT,n = 4)75%。术后1年复发率分别为:AF(n = 4)100%,典型AFL(n = 20)25%,非典型AFL(n = 2)50%,AT(n = 7)28.6%。无患者发生AVNRT复发(n = 2)。围手术期有7例(18.4%)失代偿,需要启动升压药并转入重症监护病房,1例(2.6%)围手术期死亡。

结论

该研究表明,1组PH患者行室上性心动过速消融术相对安全有效,尽管与普通人群相比初始成功率较低且临床失代偿风险较高。与普通人群相比,AF和非典型AFL消融术后1年复发率较高,典型AFL和AT消融术后复发率相似。

相似文献

1
Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension.1型肺动脉高压患者室上性心动过速消融术后的结局
Cardiol Res. 2023 Oct;14(5):403-408. doi: 10.14740/cr1556. Epub 2023 Oct 21.
2
Benefits from catheter ablation in patients with pulmonary hypertension: Recent advances.肺动脉高压患者导管消融治疗的获益:最新进展。
Kardiol Pol. 2024;82(6):602-608. doi: 10.33963/v.phj.101246.
3
Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.经导管消融治疗室上性心动过速的长期症状改善和患者满意度:来自德国消融登记处的见解。
Eur Heart J. 2017 May 1;38(17):1317-1326. doi: 10.1093/eurheartj/ehx101.
4
Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias.房性心律失常患者心房颤动的发生率及预测因素及其对长期生存的影响。
Europace. 2014 Oct;16(10):1508-14. doi: 10.1093/europace/euu129. Epub 2014 Jun 6.
5
Ablation outcomes for atypical atrial flutter versus recurrent atrial fibrillation following index pulmonary vein isolation.肺静脉隔离术后非典型房性心动过速与复发性心房颤动的消融结果对比。
J Cardiovasc Electrophysiol. 2021 Jun;32(6):1631-1639. doi: 10.1111/jce.15051. Epub 2021 May 5.
6
Catheter Ablation for Atrial Fibrillation in Patients ≤30 Years of Age.30岁及以下患者心房颤动的导管消融治疗
Am J Cardiol. 2022 Mar 1;166:53-57. doi: 10.1016/j.amjcard.2021.11.020. Epub 2021 Dec 30.
7
[Catheter ablation in supraventricular tachycardia].[导管消融治疗室上性心动过速]
Z Kardiol. 1996;85 Suppl 6:45-60.
8
Catheter ablation of atrial fibrillation in cardiac amyloidosis.心脏淀粉样变性患者的心房颤动导管消融。
Pacing Clin Electrophysiol. 2020 Sep;43(9):913-921. doi: 10.1111/pace.13992. Epub 2020 Aug 9.
9
Safety and effectiveness of a novel dielectric mapping system: one-year, two chinese centers experiences.新型介电标测系统的安全性和有效性:来自两家中国中心的一年经验。
BMC Cardiovasc Disord. 2022 Aug 3;22(1):352. doi: 10.1186/s12872-022-02790-8.
10
The results of radiofrequency catheter ablation of supraventricular tachycardia in children.儿童室上性心动过速的射频导管消融结果
Pacing Clin Electrophysiol. 2007 May;30(5):655-61. doi: 10.1111/j.1540-8159.2007.00727.x.

本文引用的文献

1
Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association.非心脏手术相关肺动脉高压的评估与管理:美国心脏协会科学声明
Circulation. 2023 Apr 25;147(17):1317-1343. doi: 10.1161/CIR.0000000000001136. Epub 2023 Mar 16.
2
10-year single center experience of catheter ablation of focal atrial tachycardia.局灶性房性心动过速导管消融的10年单中心经验
J Interv Card Electrophysiol. 2023 Aug;66(5):1135-1144. doi: 10.1007/s10840-022-01416-5. Epub 2022 Nov 18.
3
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
4
Outcomes of supraventricular tachycardia ablation: Results from the Singapore ablation and cardiac devices registry.室上性心动过速消融治疗的结果:来自新加坡消融和心脏器械注册中心的结果。
Pacing Clin Electrophysiol. 2022 Jan;45(1):50-58. doi: 10.1111/pace.14410. Epub 2021 Dec 8.
5
Long term prognosis in patients with pulmonary hypertension undergoing catheter ablation for supraventricular tachycardia.肺动脉高压患者行导管消融治疗室上性心动过速的长期预后。
Sci Rep. 2021 Aug 10;11(1):16176. doi: 10.1038/s41598-021-95508-3.
6
Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome.肺动脉高压患者室上性心动过速的射频导管消融:可行性及长期预后
Front Physiol. 2021 Jun 18;12:674909. doi: 10.3389/fphys.2021.674909. eCollection 2021.
7
Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement.肺高血压患者非心胸、非产科手术的围手术期管理:系统评价和专家共识声明。
Br J Anaesth. 2021 Apr;126(4):774-790. doi: 10.1016/j.bja.2021.01.005. Epub 2021 Feb 19.
8
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
9
2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).2019年欧洲心脏病学会(ESC)室上性心动过速患者管理指南 欧洲心脏病学会(ESC)室上性心动过速患者管理工作组
Eur Heart J. 2020 Feb 1;41(5):655-720. doi: 10.1093/eurheartj/ehz467.
10
Japan ablation registry: cryoablation in atrioventricular nodal reentrant tachycardia ("JARCANRET study"): results from large multicenter retrospective investigation.日本消融登记处:房室结折返性心动过速中的冷冻消融(“JARCANRET 研究”):大型多中心回顾性研究结果。
J Interv Card Electrophysiol. 2020 Sep;58(3):289-297. doi: 10.1007/s10840-019-00585-0. Epub 2019 Jul 31.